3 Healthcare Stock Stories for Friday Perusal

Warner Chilcott Limited (NASDAQ:WCRX): Current price $14.20

The firm announced Friday that the FDA has okayed a 200 mg strength of Doryx (doxycycline hyclate) Delayed-Release Tablets. The tablets are a tetracycline-class oral antibiotic. Warner Chilcott expects that it will commercially launch Doryx 200 mg Tablets in July.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

WCRX

Elan Corporation (NYSE:ELN): Current price $12

Elan reports that at an Extraordinary General Meeting held earlier on Friday, the sole ordinary resolution to approve the Tender Offer to acquire ordinary shares was overwhelmingly passed with more than 99 percent of the shares voted to pass of the resolution. The full text of the resolution was included in the notice of the EGM dated March 14th, which is available on the firm’s website.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ELN

XenoPort (NASDAQ:XNPT): Current price $7.27

On Friday, XenoPort reported that GlaxoSmithKline (NYSE:GSK), who holds commercialization rights to Horizant (gabapentin enacarbil) Extended-Release Tablets in the United States during a transition period ending on April 30, has suffered manufacturing delays resulting in a stockout of Horizant. GSK continues to have sole responsibility for the manufacture and supply of Horizant during this transition period, and is endeavoring to resolve the manufacturing problems with its contract manufacturer. The timing is uncertain, but XenoPort is hopeful that new inventory of Horizant will be available in pharmacies in June.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

XNPT

Don’t Miss: Would Obama’s Budget Make a Healthcare Workforce Crisis Worse?

More Articles About:   ,  

More from The Cheat Sheet